Charles Schwab Trust Co Acquires 15,502 Shares of AbbVie Inc. $ABBV

Charles Schwab Trust Co raised its holdings in AbbVie Inc. (NYSE:ABBV) by 93.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 32,105 shares of the company’s stock after buying an additional 15,502 shares during the period. Charles Schwab Trust Co’s holdings in AbbVie were worth $7,434,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ABBV. Hobart Private Capital LLC raised its holdings in AbbVie by 4.4% during the third quarter. Hobart Private Capital LLC now owns 1,127 shares of the company’s stock worth $261,000 after acquiring an additional 48 shares in the last quarter. Rise Advisors LLC increased its position in shares of AbbVie by 3.4% during the 3rd quarter. Rise Advisors LLC now owns 1,451 shares of the company’s stock worth $336,000 after purchasing an additional 48 shares during the last quarter. Sivia Capital Partners LLC raised its stake in shares of AbbVie by 1.1% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,571 shares of the company’s stock worth $848,000 after purchasing an additional 51 shares in the last quarter. FF Advisors LLC raised its stake in shares of AbbVie by 3.6% during the 2nd quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock worth $286,000 after purchasing an additional 53 shares in the last quarter. Finally, Landaas & Co. WI ADV boosted its holdings in shares of AbbVie by 1.1% in the 2nd quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company’s stock valued at $920,000 after buying an additional 53 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ABBV has been the topic of a number of recent analyst reports. DZ Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a report on Tuesday, November 4th. Hsbc Global Res upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 10th. Morgan Stanley upped their target price on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Erste Group Bank cut AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Finally, Raymond James Financial set a $256.00 price objective on AbbVie in a research note on Monday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $245.84.

AbbVie Stock Up 2.1%

AbbVie stock opened at $227.44 on Monday. The stock has a market cap of $401.98 billion, a P/E ratio of 172.30, a P/E/G ratio of 1.29 and a beta of 0.36. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The company’s 50-day moving average price is $226.63 and its two-hundred day moving average price is $211.31.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the company posted $3.00 earnings per share. The business’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is 496.97%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.